Citations

Clear

65 citation(s) found for "Fox, Michael".

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α -Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
Chahine, Lana M. , Beach, Thomas G. , Seedorff, Nicholas , Caspell‐Garcia, Chelsea , Coffey, Christopher S. , Brumm, Michael C. , Linder, Carly, Mosovsky, Sherri, Riss, Holly, Ecklund, Dixie , Seibyl, John , Jennings, Danna , Arnedo, Vanessa , Riley, Lindsey , Dave, Kuldip D. , Mollenhauer, Brit , study, on behalf of the Systemic sSynuclein Sampling, Adler, Charles H. , Serrano, Geidy E. , Foroud, Tatiana , study, on behalf of the Systemic sSynuclein Sampling

Mayo Clinic

Journal of Parkinson’s Disease | September 21, 2018 | Volume: 8 | Issue: 4 | Pages: 517-527

10.3233/jpd-181434 | PMID 30248065 Get It

Background: α-synuclein is a lead Parkinson’s disease (PD) biomarker. There are conflicting reports regarding accuracy of α-synuclein in different tissues and biofluids as a PD biomarker, and the within-subject anatomical distribution of α-synuclein is not well described. The Systemic Synuclein Sampling Study (S4) aims to address these gaps in knowledge. The S4 is a multicenter, cross-sectional, observational study evaluating α-synuclein in multiple tissues and biofluids in PD and healthy controls (HC). Objective: To describe the baseline characteristics of the S4 cohort and safety and feasibility of this study. Methods: Participants underwent motor and non-motor clinical assessments, dopamine transporter SPECT, biofluid collection (cerebrospinal fluid, saliva, and blood), and tissue biopsies (skin, sigmoid colon, and submandibular gland). Biopsy adequacy was determined based on presence of adequate target tissue. Tissue sections were stained with the 5C12 monoclonal antibody against unmodified α-synuclein. All specimens were acquired and processed in a standardized manner. Adverse events were systematically recorded. Results: The final cohort consists of 82 participants (61 PD, 21 HC). In 68 subjects (83%), all types of specimens were obtained but only 50 (61%) of subjects had all specimens both collected and evaluable for α-synuclein. Mild adverse events were common, especially for submandibular gland biopsy, but only 1 severe adverse event occurred. Conclusion: Multicenter tissue and biofluid sampling for α-synuclein is feasible and generally safe. S4 will inform understanding of the concurrent distribution of α-synuclein pathology and biomarkers in biofluids and peripheral nervous system in PD.
Selective application of fully covered biliary stents and narrow-diameter esophageal stents for proximal esophageal indications
Pang, Maoyin , Clayton, Donnesha , Brahmbhatt, Bhaumik , Woodward, Timothy A., Bartel, Michael J.

Mayo Clinic

Endoscopy | July 13, 2018 | Volume: 51 | Issue: 02 | Pages: 169-173

10.1055/a-0650-4588 | PMID 30005444 Get It

Abstract Background Proximal esophageal stents are poorly tolerated and have a high risk of complications. We report our experience using fully covered, biliary, self-expandable metal stents (B-SEMS) and narrow-diameter, esophageal, self-expandable metal stents (NDE-SEMS) for this group of patients. Methods 24 patients underwent placement of B-SEMS or NDE-SEMS for proximal esophageal lesions between 1 January 2011 and 31 July 2016. The outcomes included improvement of dysphagia, healing of fistulas, and adverse events. Results 10 patients received B-SEMS and 14 had NDE-SEMS. Median follow-up time was 11.5 months (range 0.5 – 62 months). In both cohorts, stents were left in place for a mean of 6 weeks. The dysphagia score decreased in 7 (70 %) and 10 (71.4 %) patients, and fistulas resolved in 3/5 (60.0 %) and 5/8 (62.5 %) patients with B-SEMS and NDE-SEMS, respectively. Stent migration occurred in three patients (30.0 %) with B-SEMS and five patients (35.7 %) with NDE-SEMS. Conclusions Both stents were well tolerated and resulted in overall improvement of dysphagia in 70.8 % of patients. B-SEMS appeared to be more favorable for cervical esophageal lesions with narrower diameters, while NDE-SEMS may be better for more distal lesions.
Outcome of long benign esophageal strictures undergoing endoscopictherapy: a tertiary center experience
Pang, Maoyin , Brand, Eelco C. , Brahmbhatt, Bhaumik , Patel, Krupa , Simons-Linares, C. Roberto , Wolfsen, Herbert C. , Wallace, Michael B. , Woodward, Timothy A., Wallace, Michael B , Bartel, Michael J. , Raimondo, Massimo

Mayo Clinic

Diseases of the Esophagus | May 1, 2018 | Volume: 31 | Issue: 10 | Pages: No page available

10.1093/dote/doy040 | PMID 29718161 Get It

Transatlantic Differences in Management of Carotid Stenosis: BRIDGing the Gap in StrokE Management (BRIDGE) Project
Balucani, Clotilde , Arnedo, Vanessa , Weedon, Jeremy, Mas, Jean‐Louis , Brown, Martin M. , Grotta, James C. , Gonzales, Nicole R. , Hacke, Werner , Brott, Thomas G. , Brott, Thomas, Leys, Didier , Levine, Steven R. , Grotta, James C

Mayo Clinic

The Neurohospitalist | January 19, 2018 | Volume: 8 | Issue: 3 | Pages: 113-123

10.1177/1941874417747772 | PMID 29977441 Get It

Background and Purpose: Management of carotid stenosis remains controversial despite several trials evaluating carotid endarterectomy (CEA) and carotid angioplasty/stenting (CAS). We compared attitudes in the management of carotid stenosis between selected experts within Europe and North America. Methods: A 3-phase Delphi survey was e-mailed to select stroke experts from Europe (n = 390) and North America (n = 289). Those completing the initial survey were shown all responses after each survey round. Consensus was defined as ≥80% agreement. Results: For phases 1, 2, and 3, response rates were 32%, 62%, and 73%, respectively. Overall, 100 (15%) of 679 participated in all 3 phases, 19% Europeans versus 9% North Americans ( P = .0007). The European group reached consensus in 6 of 15 statements; The North American group reached consensus in 4 of 15. Ninety percentage of Europeans versus 70% of North Americans ( P = .017) stated CEA is superior to CAS for symptomatic carotid stenosis. This difference was not significant in the final model (adjusted odds ratio: 3.72 [95% confidence interval: 0.95-14.5]). Sixty-nine percentage of North Americans agreed there is a stronger indication for CAS over CEA in patients younger than 65 years for symptomatic carotid stenosis, whereas 55% of Europeans ( P = .023) disagreed. For asymptomatic carotid stenosis, when asked how likely they would recommend CAS, 62% North Americans said “sometimes” versus 60% of Europeans said “never” ( P = .06). Conclusion: The majority of North American and European respondents did not consider the 2 procedures equivalent and seemed to indicate that CEA was preferred for the management of carotid stenosis. These findings need to be further explored to help establish evidence-based guidelines.
Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)
Malik, Imtiaz A. , Hecht, J. Randolph, Patnaik, A., Croghan, Gary A., Navale, Lynn, MacDonald, Michael R. , Jerian, S., Meropol, Neal J. , Patnaik, Amita , Venook, Alan P. , Berlin, Jordan D.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3520-3520

10.1200/jco.2005.23.16_suppl.3520 Get It

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Lesokhin, Alexander M. , Ansell, Stephen M. , Armand, Philippe , Halwani, Ahmad , Gutierrez, Martin , Millenson, Michael, Cohen, Adam D. , Lebovic, Daniel, Dhodapkar, Madhav V. , Avigan, David , Chapuy, Bjoern , Ligon, Azra H. , Freeman, Gordon J. , Cattry, Deepika, Zhu, Lili, Grosso, Joseph F., Garelik, M. Brigid, Borrello, Ivan , Timmerman, John M. , Scott, Emma C. , Millenson, Michael M, Schuster, Stephen J. , Dhodapkar, Madhav, Rodig, Scott J, Bradley Garelik, M Brigid, Shipp, Margaret A, Timmerman, John, Scott, Emma , Rodig, Scott J , Zhu, Lili, Shipp, Margaret Ann , Lesokhin, Alexander M , Cohen, Adam D

Mayo Clinic

Journal of Clinical Oncology | June 6, 2016 | Volume: 34 | Issue: 23 | Pages: 2698-2704

10.1200/jco.2015.65.9789 | PMID 27269947 Get It

Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in hematologic malignancies. Methods In this phase I, open-label, dose-escalation, cohort-expansion study, patients with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti–PD-1 monoclonal antibody nivolumab at doses of 1 or 3 mg/kg every 2 weeks. This study aimed to evaluate the safety and efficacy of nivolumab and to assess PD-L1/PD-L2 locus integrity and protein expression. Results Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27). Patients had received a median of three (range, one to 12) prior systemic treatments. Drug-related adverse events occurred in 51 (63%) patients, and most were grade 1 or 2. Objective response rates were 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively. Median time of follow-up observation was 66.6 weeks (range, 1.6 to 132.0+ weeks). Durations of response in individual patients ranged from 6.0 to 81.6+ weeks. Conclusion Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.
Management of colorectal T1 carcinoma treated by endoscopic resection from the Western perspective
Bartel, Michael J. , Brahmbhatt, Bhaumik , Wallace, Michael B. , Brahmbhatt, Bhaumik S, Wallace, Michael B

Mayo Clinic

Digestive Endoscopy | December 31, 2015 | Volume: 28 | Issue: 3 | Pages: 330-341

10.1111/den.12598 | PMID 26718885 Get It

Detection of early colorectal cancer is expected to rise in light of national colorectal cancer screening programs. This The present review article delineates current endoscopic risk assessments, differentiating invasive from non‐invasive neoplasia, for high likelihood of lymph node metastasis in early colorectal cancer, also termed high‐risk early colorectal cancer, and endoscopic and surgical resection methods from a Western hemisphere perspective.
Clinical Characteristics and Outcomes of Patients with and without Diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) Trial
MacDonald, Michael R. , She, Lilin , Doenst, Torsten , Binkley, Philip F. , Rouleau, Jean L. , Tan, Ru‐San , Lee, Kerry L., Miller, Alan B. , Szalewska, Dominika , Waclawiw, Myron A., Castelvecchio, Serenella , Adlbrecht, Christopher , Michler, Robert E. , Oh, Jae K. , Petrie, Mark C. , Sopko, George S. , Dąbrowski, Rafał , Velazquez, Eric J. , Petrie, Mark C

Mayo Clinic

European Journal of Heart Failure | May 26, 2015 | Volume: 17 | Issue: 7 | Pages: 725-734

10.1002/ejhf.288 | PMID 26011509 Get It

Abstract Aims Hypothesis 1 of the Surgical Treatment for Ischemic Heart Failure (STICH) trial enrolled 1212 patients with an LVEF of ≤35% and CAD amenable to coronary artery bypass grafting (CABG). Patients were randomized to CABG and optimal medical therapy (MED) or MED alone. The objective was to assess whether or not patients with diabetes mellitus (DM) enrolled in the STICH trial would have greater benefit from CABG than patients without DM. Methods and results The characteristics and clinical outcomes of patients with and without DM randomized to CABG and MED or MED alone were compared. DM was present in 40%. At baseline, patients with DM had more triple vessel CAD, higher LVEF, and smaller left ventricular volumes. In patients with DM, the primary outcome of all-cause mortality occurred in 39% of patients in the MED group and 39% in the CABG group [hazard ratio (HR) with CABG 0.96, 95% confidence interval (CI) 0.73–1.26]. In patients without DM, the primary outcome occurred in 41% of patients in the MED group and 32% in the CABG group (HR with CABG 0.80, 95% CI 0.63–1.02). While numerically it would appear that the treatment effect of CABG is blunted in patients with DM, there was no significant interaction between DM and treatment group on formal statistical testing. Conclusions Patients with DM enrolled in the STICH trial had more triple vessel disease, smaller hearts, and higher LVEF than those without DM. CABG did not exert greater benefit in patients with DM.